- Anniversary/History
- Membership
- Publications
- Resources
- Education
- Events
- Advocacy
- Careers
- About
- For Pain Patients and Professionals
Macimorelin is an orally active ghrelin receptor agonist indicated for the diagnosis of adult growth hormone (GH) deficiency in the United States. This phase 1 study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of macimorelin (including a supratherapeutic dose to be used in a thorough QT trial) in healthy adults.